Compile Data Set for Download or QSAR
maximum 50k data
Found 63 Enz. Inhib. hit(s) with all data for entry = 50049291
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM171332(US9085555, 762)
Affinity DataIC50:  6nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM171332(US9085555, 762)
Affinity DataIC50:  6nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM171239(US9085555, 669)
Affinity DataIC50:  10nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM171350(1-(2-((1R,3S,5R)-3-((6-Bromopyridin-2-yl)carbamoyl...)
Affinity DataIC50:  11nMAssay Description:Evaluated for the Non-competitive inhibition constant Ki against TdR varied rat cytoplasmic soluble thymidine kinaseMore data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM171350(1-(2-((1R,3S,5R)-3-((6-Bromopyridin-2-yl)carbamoyl...)
Affinity DataIC50:  11nMAssay Description:Inhibition of complement factor D in human whole blood assessed as decrease in zymosan-induced AP activation mediated soluble MAC complex formation p...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50238248(CHEMBL4094108)
Affinity DataIC50:  12nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50238246(CHEMBL4098439)
Affinity DataIC50:  14nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50238247(CHEMBL4081888)
Affinity DataIC50:  15nMAssay Description:Binding affinity against alpha-2 adrenergic receptor from calf cerebral cortex, using [3H]clonidine as the radioligandMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50238246(CHEMBL4098439)
Affinity DataIC50:  22nMAssay Description:Inhibition of complement factor D in human whole blood assessed as decrease in zymosan-induced AP activation mediated soluble MAC complex formation p...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50238245(CHEMBL4070311)
Affinity DataIC50:  23nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50238247(CHEMBL4081888)
Affinity DataIC50:  35nMAssay Description:Inhibition of complement factor D in human whole blood assessed as decrease in zymosan-induced AP activation mediated soluble MAC complex formation p...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50238252(CHEMBL4061643)
Affinity DataIC50:  45nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50238244(CHEMBL4065529)
Affinity DataIC50:  50nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM170763(US9085555, 191)
Affinity DataIC50:  50nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM171323(US9085555, 753)
Affinity DataIC50:  66nMAssay Description:Binding affinity against alpha-2 adrenergic receptor from calf cerebral cortex, using [3H]clonidine as the radioligandMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM171323(US9085555, 753)
Affinity DataIC50:  66nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50238251(CHEMBL4095470)
Affinity DataIC50:  150nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM171239(US9085555, 669)
Affinity DataIC50:  150nMAssay Description:Inhibition of complement factor D in human whole blood assessed as decrease in zymosan-induced AP activation mediated soluble MAC complex formation p...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50238250(CHEMBL4075355)
Affinity DataIC50:  150nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C9(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50238245(CHEMBL4070311)
Affinity DataIC50:  150nMAssay Description:Inhibition of CYP2C9 (unknown origin) using diclofenac as substrateMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50238244(CHEMBL4065529)
Affinity DataIC50:  210nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain (G24 to A253 residues) expressed in expressed in Escherichia coli(Rosetta) using...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50238248(CHEMBL4094108)
Affinity DataIC50:  250nMAssay Description:Inhibition of complement factor D in human whole blood assessed as decrease in zymosan-induced AP activation mediated soluble MAC complex formation p...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C9(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50238248(CHEMBL4094108)
Affinity DataIC50:  250nMAssay Description:Inhibition of CYP2C9 (unknown origin) using diclofenac as substrateMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM170709(US9085555, 137)
Affinity DataIC50:  300nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50238276(CHEMBL4075037)
Affinity DataIC50:  320nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50238275(CHEMBL4076955)
Affinity DataIC50:  370nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM170904(US9085555, 332)
Affinity DataIC50:  450nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM170966(US9085555, 396)
Affinity DataIC50:  500nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM60517(US9085555, 124)
Affinity DataIC50:  500nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50238245(CHEMBL4070311)
Affinity DataIC50:  587nMAssay Description:Inhibition of complement factor D in human whole blood assessed as decrease in zymosan-induced AP activation mediated soluble MAC complex formation p...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50238249(CHEMBL4068741)
Affinity DataIC50:  650nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM170796(US9085555, 224)
Affinity DataIC50:  700nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C9(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50238244(CHEMBL4065529)
Affinity DataIC50:  800nMAssay Description:Inhibition of CYP2C9 (unknown origin) using diclofenac as substrateMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM60517(US9085555, 124)
Affinity DataIC50:  800nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain (G24 to A253 residues) expressed in expressed in Escherichia coli(Rosetta) using...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM170729(US9085555, 157)
Affinity DataIC50:  850nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50238244(CHEMBL4065529)
Affinity DataIC50:  1.25E+3nMAssay Description:Inhibition of complement factor D in human whole blood assessed as decrease in zymosan-induced AP activation mediated soluble MAC complex formation p...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM170821(US9085555, 249)
Affinity DataIC50:  1.40E+3nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C9(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM170763(US9085555, 191)
Affinity DataIC50:  2.50E+3nMAssay Description:Evaluated for the mixed objective Non-competitive inhibition constant Ki against ATP varied cytoplasmic soluble thymidine kinaseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C9(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM60517(US9085555, 124)
Affinity DataIC50:  3.40E+3nMAssay Description:Inhibition of CYP2C9 (unknown origin) using diclofenac as substrateMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C9(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM171332(US9085555, 762)
Affinity DataIC50:  4.00E+3nMAssay Description:Inhibition of CYP2C9 (unknown origin) using diclofenac as substrateMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C9(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50238246(CHEMBL4098439)
Affinity DataIC50:  4.30E+3nMAssay Description:Inhibition of CYP2C9 (unknown origin) using diclofenac as substrateMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM203868((S)-N2-benzhydryl-N1-(1-methyl-1H-indol-3-yl)pyrro...)
Affinity DataIC50:  5.80E+3nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetProstaglandin G/H synthase 1(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM60517(US9085555, 124)
Affinity DataIC50:  6.40E+3nMAssay Description:Inhibition of COX1 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetAdenosine receptor A3(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM60517(US9085555, 124)
Affinity DataIC50:  8.80E+3nMAssay Description:Antagonist activity at adenosine 3 receptor (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C9(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM170966(US9085555, 396)
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of CYP2C9 (unknown origin) using diclofenac as substrateMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C9(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM170821(US9085555, 249)
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of CYP2C9 (unknown origin) using diclofenac as substrateMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM203865(Methyl (S)-2-((2-((3-(trifluoromethoxy)phenyl)carb...)
Affinity DataIC50:  1.40E+4nMAssay Description:Binding affinity against alpha-2 adrenergic receptor from calf cerebral cortex, using [3H]prazosin as the radioligandMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
TargetCytochrome P450 3A4(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM171350(1-(2-((1R,3S,5R)-3-((6-Bromopyridin-2-yl)carbamoyl...)
Affinity DataIC50:  1.70E+4nMAssay Description:Inhibition of CYP3A4 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2D6(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM171350(1-(2-((1R,3S,5R)-3-((6-Bromopyridin-2-yl)carbamoyl...)
Affinity DataIC50: >2.00E+4nMAssay Description:Inhibition of CYP2D6 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50238277(CHEMBL4103449)
Affinity DataIC50:  2.00E+4nMAssay Description:Inhibition of recombinant human complement factor D catalytic domain (G24 to A253 residues) expressed in expressed in Escherichia coli(Rosetta) using...More data for this Ligand-Target Pair
Displayed 1 to 50 (of 63 total ) | Next | Last >>
Jump to: